Financing

#Artificial intelligence (AI) #Chai Discovery #Drug discovery #Financing

Chai Discovery announces $130m series B financing

Chai Discovery has announced a $130 million Series B financing round co-led by Oak HC/FT and General Catalyst.   The news follows Chai’s most recent announcement, where the company showed its latest models can now design molecules with important “developability” properties and tackle “hard-to-drug” targets that have historically been challenging for… Read More

#Business & Investment #News

Cell therapy platform
#Cell therapy #Cellular Origins #Financing

Cellular Origins complete $40 million financing round  

TTP company Cellular Origins has completed a $40 million Series A financing round to accelerate its development of scalable cell therapy manufacture.  The Series A financing was led by Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation, with the syndicate comprising Highland Europe, BGF, NYBC Ventures, and… Read More

#Business & Investment #News

#Financing #Investment #Neurology #OTR Therapeutics

OTR Therapeutics raises $100 million in series A financing

OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing.   The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital.  Founded in March 2025, Shanghai-based OTR Therapeutics aims to discover and acquire… Read More

#Business & Investment #News #Start-up Zone

#Biotech #Financing #TRIMTECH Therapeutics

TRIMTECH Therapeutics appoints new Chair of the Board 

Biotechnology company TRIMTECH Therapeutics has appointed Alison Lawton as Chair of the Board as the company moves to advance its portfolio of disease-modifying therapies.  Lawton arrives at TRIMTECH with more than 35 years of global pharma and biotech leadership expertise, leading global regulatory strategy for numerous product approvals and gaining extensive… Read More

#News

#AL Amyloidosis #Clinical trial #Financing

Protego raises $130 million to advance AL amyloidosis treatment 

Biotechnology company Protego Biopharma has raised $130 million to advance its first-in-class AL amyloidosis programme to clinical trial.  The proceeds from the over-subscribed Series B financing round will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis. PROT-001 works by stabilising immunoglobulin light chains and preventing amyloid buildup, addressing disease at its root cause… Read More

#Business & Investment #News

ALS concept
#ALS #Axoltis Pharma #Financing

Axoltis Pharma raises €18 million to advance ALS drug 

Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round was co-led by FIDAT Ventures and Cenitz with… Read More

#Business & Investment #News

#Financing #Oncology #One-carbon Therapeutics #Solid tumours

One-carbon closes oversubscribed private placement financing

One-carbon Therapeutics has closed an oversubscribed 153 million SEK ($16.2 million) private placement financing round supported by current and new investors and private Swedish family offices.  The company says it will use the net proceeds from the private placement to strengthen its financial position and expand its ongoing Phase I/II… Read More

#Business & Investment #News

Cancer research in laboratory
#Breast cancer #Cancer research #Financing

Zetagen raises $12 million to advance breast cancer treatment 

Biopharmaceutical company Zetagen Therapeutics has raised over $12 million to proceed with first-of-its-kind, intratumoural treatments for metastatic and primary breast cancer.  The company announced the closing of its Series B1 financing round, raising $12.9 million. Proceeds will support the advancement of Zetagen’s lead candidate, ZetaMet (Zeta-BC-003), towards commercialisation, the clinical development of ZetaMast (Zeta-MBC-005), and the completion of preclinical studies and GMP manufacturing of ZetaPrime (Zeta-PBC-007).  The… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Business #Clinical development #Financing

myTomorrows to use funding to ‘transform’ patient therapy access 

Health technology company myTomorrows has secured $29 million in funding to develop its AI-driven global platform, aiming to bring patients access to innovative therapies.  The company aims to develop a platform to bridge the gap between scientific advancement and patient access to pre-approval treatments. This includes drug candidates undergoing clinical… Read More

#Business & Investment #News

Structure of the eye
#Biotech #Financing #Stargardt disease

AAVantgarde Bio raises $141 million for IRD trials

Biotechnology company AAVantgarde Bio has raised $141 million to advance its clinical programmes in inherited retinal disorders (IRD) Stargardt disease and Usher 1B syndrome.  The investment follows a successful Series B financing round, led by Schroders Capital and existing investors Atlas Venture and Forbion.   AAVantgarde aims to use the proceeds to complete the clinical study of AAVB-039… Read More

#Business & Investment #News

#antibiotic #Clinical trial #Financing

smartbax raises €4.7 million to advance antibiotic compound 

Biotechnology company smartbax has announced it has raised €4.7 million to advance a novel antibiotic compound through preclinical stage.  The pre-Series A financing round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors.  The financing will support… Read More

#Business & Investment #News

Parkinson's disease
#Financing #Mission Therapeutics #Parkinson's

Mission Therapeutics raises $13.3 million for Parkinson’s treatment

Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential process cells use… Read More

#Business & Investment #News

Ovarian cancer cells
#Antibody drug conjugate (ADC) #Cancer research #Financing

Tubulis raises record $361 million to develop ADC candidate TUB-040

Biotechnology company Tubulis has announced it has raised a record $361 million in financing to expand its clinical development of the antibody-drug conjugate (ADC) candidate TUB-040.  The financing represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally. The financing… Read More

#Business & Investment #News

GBP pound sterling funding
#Biotechnology #Financing #Fundraising #Oncology

Trogenix secures £70m to advance oncology pipeline

Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.   The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The round also included… Read More

#Business & Investment #News

Chronic gout
#Crystalys Therapeutics #Financing #Gout #Start-ups

Crystalys Therapeutics launches to develop gout treatment

Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout.   The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive… Read More

#Business & Investment #News #Start-up Zone